Tagged with BALT

France Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products…

Baltics In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in Lithuania and Estonia in 2016, but only 38 and 30 were made available to patients respectively. Latvia fares even worse,…

Latvia The top 20 companies in the Latvian pharmaceutical market for 2017, sorted by total value and market share, with data on year-on-year growth. American giant AbbVie ranks first, with an almost six percent market share and astounding 65 percent year-on-year growth, followed by TEVA and Sanofi.

Baltics As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they require for a new age of medical science. “There are a number of emerging trends underway that are forcing companies…

Baltics Vasily and Svetlana Bankovsky, founders of Biosan, talk about the company’s philosophy to develop modern, exciting personal products for sample preparation in the field of genomics, proteomics and cellomics and about their ambition to grow domestically and internationally. Vasily and Svetlana, can you give our international readers a brief overview…

Lithuania Lukas Savickas, advisor to the prime minister of Lithuania, highlights the changes needed for the Lithuanian life science industry to become more competitive, while discussing the opportunities awaiting companies willing to invest in the country. Can you please introduce yourself to our international audience as well as the main points…

Latvia Anda Čakša, Latvia’s minister of health since 2016, discusses her current priorities, regulatory reform, areas of strengths and weaknesses in the nation’s healthcare infrastructure, e-health, and combating the threat of non-communicable diseases. What have been your main achievements since assuming position as health minister back in 2016? “The e-health system…

Poland Hubert Niemyjski, country manager of Coloplast Poland and the Baltics, highlights the large differences between the market landscape of the company’s three pillars; ostomy, wound and continence care. Additionally, he discusses the importance of taking into consideration QOL when making reimbursement decisions and the amazing potential of the Polish market…

Estonia Rauno Oja, managing director of AS EGeen, discusses the company’s geographical expansion during his tenure, turning to an international full-service CRO, EGeen’s commitment to high standards, and engagement with the community; carrying out communication activities on the ground in each country in which it operates. Rauno, you have worked for…

Lithuania Lithuania’s key economic indicators between 2015 and 2018: GDP growth, inflation, unemployment rate, and government budget. Lithuania’s pharma market in terms of both volume and value. Spending on public health in Lithuania. The Lithuanian pharma market split by dispensing types. The public funding of health and pharmaceuticals in Lithuania. Healthcare…

Lithuania The Top 20 pharma companies in Lithuania by value for 2017. J&J leads the way with a value of around EUR 35 million and market share of 6.3% bolstered by 63% year-on-year growth. Berin Chemie ranks second, while Novartis ranks third.

Baltics Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration with key stakeholders to enhance the uptake of biosimilars. Roland, prior to joining Sandoz as Cluster Head Baltics you were…